KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Common Equity (2016 - 2026)

Pacira BioSciences has reported Common Equity over the past 17 years, most recently at $653.9 million for Q1 2026.

  • For Q1 2026, Common Equity fell 18.11% year-over-year to $653.9 million; the TTM value through Mar 2026 reached $653.9 million, down 18.11%, while the annual FY2025 figure was $693.1 million, 10.95% down from the prior year.
  • Common Equity for Q1 2026 was $653.9 million at Pacira BioSciences, down from $693.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $892.2 million in Q1 2024 and troughed at $653.9 million in Q1 2026.
  • A 5-year average of $777.6 million and a median of $770.1 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: increased 16.16% in 2024 and later fell 18.11% in 2026.
  • Year by year, Common Equity stood at $775.0 million in 2022, then grew by 12.27% to $870.1 million in 2023, then decreased by 10.55% to $778.3 million in 2024, then dropped by 10.95% to $693.1 million in 2025, then decreased by 5.66% to $653.9 million in 2026.
  • Business Quant data shows Common Equity for PCRX at $653.9 million in Q1 2026, $693.1 million in Q4 2025, and $727.2 million in Q3 2025.